Tian Ge Interactive Holdings Limited ("Tian Ge" or the "Group", 1980.HK, TGRVY.US), the largest "many-to-many" live social communities platform in China, today announced the unaudited consolidated results for the three months ended March 31, 2015.

Financial Highlights of the First Quarter of 2015

Total revenues up 8.1% to RMB185.5 million year-on-year ("YoY") and 6.1% quarter-on-quarter ("QoQ") from RMB171.6 million and RMB174.8 million in the first quarter and fourth quarter of 2014 respectively, mainly driven by the success of our mobile games business. Excluding the VAT effect, revenue increased by 14.1% YoY, as our revenues are recorded as net off 6% VAT tax after June 1, 2014.

Revenue from games increased by 66.7% YoY to RMB20.9 million. 

Gross profit increased by 8.4% YoY and 9.0% QoQ to RMB156.5 million from RMB144.3 million and RMB143.5 million in the first quarter and fourth quarter of 2014, respectively.

Adjusted EBITDA increased by 26.0% YoY and 20.9% QoQ to RMB96.7 million from RMB76.8 million and RMB80.0 million, respectively.
Adjusted EBITDA margin increased to 52.1% from 44.7% in the corresponding period of 2014.
Adjusted net profit increased by 19.1% YoY and 17.6% QoQ to RMB75.1 million from RMB63.1 million and RMB 63.9 million, respectively.
Adjusted net margin increased to 40.5% from 36.7% in the corresponding period of 2014.
Adjusted diluted earnings per share was RMB 0.056 per share, as compared to RMB0.048 per share in the previous quarter
Adjusted basic earnings per share was RMB 0.061 per share, as compared to RMB0.052 per share in the previous quarter.

Mr. Mike Fu, Chairman and CEO of Tian Ge, commented, "The first quarter signals an exciting start for 2015 highlighted by strong growth of our mobile game business and in mobile paying users. We also recently completed several investments and entered into new business, expanding our live social video platform communities and realizing our vertical integration strategy. We believe the significant performance achieved in the first quarter provide a solid foundation for us to achieve consistent financial performance and to sustain strong growth in active and paying mobile users."

Business Review
In the first quarter of 2015, we continued to make healthy progress in expanding and developing our overall business. Our MAU and QPU for the live social platforms in the first quarter of 2015 grew at 34.9% and 24.2% YoY, while game platform MAU continue to grow at a triple digit growth rate. Moreover, our mobile monthly active users ("MAU") in the first quarter of 2015 increased to 14.8% from 8.0% compared to the corresponding period of 2014.

The following is a summary of the comparative figures for the periods presented above:
MAU for Tian Ge's live social platforms was approximately 16.4 million in the first quarter of 2015, representing an increase of approximately 34.9% YoY and representing an increase of 4.1% QoQ.
Quarterly Paying Users ("QPU") for Tian Ge's live social platforms was approximately 769,000 in the first quarter of 2015, representing an increase of approximately 24.2% YoY and increase of 9.1% QoQ.

The Quarterly Average Revenue Per User ("QARPU") of Tian Ge's live social platforms decreased to RMB225 in the first quarter of 2015 from RMB277 in the corresponding period of 2014, mainly due to the increase in more frequently paying mobile users.

Number of hosts on the live social platforms grew to 39,102 at March 31, 2015, representing an increase of approximately 2.1% YoY and a decrease of 1.2% QoQ.

Number of rooms on the live social platforms grew to 29,187 as at March 31, 2015, representing an increase of approximately 2.7% YoY and 3.8% QoQ, mainly because we began consolidating rooms and increasing the average room size of popular rooms in recent quarters.

Number of users on air on our live social platforms increased to approximately 629,000 in the first quarter of 2015 from approximately 566,000 in the corresponding period of the year 2014.

The percentage users on air over total MAU on the live social platforms decreased to 3.8% in the first quarter of 2015, as compared to 4.0% in the immediately preceding quarter.

The total registered users of Tian Ge as at March 31, 2015 are 278.4 million, as compared to 268.5 million as at December 31, 2014.

Financial Review

Revenues
Revenue increased by 8.1% year-on-year to RMB185.5 million for the three months ended March 31, 2015 from the corresponding period in 2014, and by 6.1% quarter-on-quarter from the three months ended December 31, 2014, driven by the success of our mobile games. Excluding the VAT effect, our revenue for the three months ended March 31, 2015 increased approximately 14.1% year-on-year compared to the corresponding period of 2014 as our revenues are recorded as net off 6% VAT tax after June 1, 2014.

Gross Profit
Gross profit increased by 8.4% to RMB156.5 million for the three months ended March 31, 2015 from RMB144.3 million in the corresponding period of 2014, with a slight increase in gross margin to 84.3% from 84.1%.

Selling & Marketing Expenses
Selling and marketing expenses decreased by 2.3% year-on-year and 13.2% quarter-on-quarter to RMB48.9 million for the three months ended March 31, 2015 from the corresponding period in 2014 and the three months ended December 31, 2014, respectively, which mainly due to the adoption of our cost control policy in 2015.

Administrative Expenses
Administrative expense increased by 12.5% year-on-year to RMB 27.5 million for the three months ended March 31, 2015 from RMB24.4 million in the corresponding period in 2014, which is primarily due to an increase in share-based compensation of RMB14.6 million. The increase is partially offset by the decrease of professional and consultancy fees of RMB8.3 million and business tax and related surcharges of RMB4.6 million benefiting from the VAT reform effective from June 1, 2014.

Research & Development Expenses
Research and development expenses increase by 35.7% year-on-year to RMB20.5 million for the three months ended March 31, 2015 from RMB15.1 million in the corresponding period in 2014, primarily due to the increase in employee benefits and new research and development investment in mobile games.

Other Gains
Other gains increased by 154.6% year-on-year to RMB15.3 million for the three months ended March 31, 2015 from RMB6.0 million for the corresponding period in 2014 which mainly caused by the increase of interest income and fair value gains of RMB8.6 million and RMB0.9 million respectively from the structured deposits.

Impact of Convertible Redeemable Preferred Shares
Upon completion of the global offering of the Company on July 9, 2014, the convertible redeemable preferred shares were automatically converted into ordinary shares on a one-to-one basis and there is no fair value gain or loss associated with these shares to be recognized in periods afterwards.

Adjusted EBITDA
Adjusted EBITDA increased by 26.0% year-on-year to RMB96.7 million for the three months ended March 31, 2015 from the corresponding period of 2014. Adjusted EBITDA margin was 52.1% for the three months ended March 31, 2015, compared to 44.7% for the corresponding period of 2014. Adjusted EBITDA represents operating profit adjusted to exclude non-cash share-based compensation expenses, listing expenses, depreciation and amortization.

Adjusted Net Income and Earnings Per Share
Adjusted net profit increased by 19.1% to RMB75.1 million for the three months ended March 31, 2015 from RMB63.1 million for the corresponding period of 2014. Adjusted diluted earnings per share is RMB0.056 for the three months ended March 31, 2015.

Adjusted net profit is not defined under IFRS, and eliminates the effect of non-cash fair value changes of convertible redeemable preferred shares, gains on repurchase of preferred shares, dividends related to redeemable preferred shares, listing expenses and non-cash share based compensation expenses.

Balance Sheet
As of March 31, 2015, the Company had cash and cash equivalents, term deposits with initial terms over 3 months, principal-protected structured deposits (recorded under current available-for-sale financial assets and current financial assets at fair value through profit or loss) in the aggregate amount of RMB1,666.5 million. The Company adopts conservative treasure policies in cash and financial management, and does not use any financial instruments for hedging purposes. All bank borrowings had been repaid before March 31, 2015.

Capital Expenditures
For the three months ended March 31, 2015, our capital expenditures were approximately RMB32.0 million, mainly related to the purchase of our new office space located in Beijing, renovation expenses, office supplies, and purchase of other network equipment. The aforementioned new office purchase transferred to our fixed assets in February 2015 with total amount of approximately RMB46.2 million.

Other Events
In March 2015, the Group announced its establishment of sponsored Level 1 ADR program in the United States. The ADRs can be traded on the US over-the counter ("OTC") market effective as of March 26, 2015 under the ticker symbol TGRVY.

In March 2015, the Group acquired 34.47% equity interest of Xi He, a company specialized in online health information services.

In March 2015, the Company issued and fully paid a special dividend of HK0.06 per ordinary share or HK$75,209,715 in total out of the Company's share premium account.

During the three months ended March 31, 2015, the Company has repurchased a total of 5,944,000 ordinary shares listed on The Stock Exchange of Hong Kong Limited with an aggregate amount of HK$20,302,780 in January 2015. All the repurchased ordinary shares had been cancelled as of March 31, 2015.

In January 2015, the Group acquired 80% of the equity interests of Jinhua Shixun, an independent third party company specialized in online live social video related technologies.

Conference Call Information
The Company will host a conference call at 9:30 p.m. ET on May 25, 2015 (9:30 a.m. Beijing Time on May 26, 2015) to review the Company's financial results and answer questions. You may access the live interactive call via:
1-888-346-8982  (U.S. Toll Free)
1-412-902-4272  (International)
852-301-84992   (Hong Kong-Local Toll)
86-105-357-3132 (Beijing-Local Toll)     
4001-201203    (China Toll Free) 
800-905945     (Hong Kong Toll Free)

Please dial-in approximately 5 minutes in advance to facilitate a timely start.

A replay will be available until 9:30 p.m. ET on June 2, 2015 and may be accessed via:
1-877-344-7529 (US Toll Free)
1-412-317-0088 (International Toll)
855-669-9658 (Canada Toll Free)
Replay access code: 10065387

A live and archived webcast of the call will be available on the Company's website at http://www.tiange.com/enInvestor/Index.aspx

About Tian Ge

Tian Ge (1980.HK) is one of the largest live social online video community platforms in China. The Company was founded in Hangzhou, China in 2008 and went public on the main board of the stock exchange of Hong Kong in July 2014. It currently operate eight "many-to-many" live social video communities on both mobile and PC, including 9158 and Sina Show, the two largest communities; and one "one-to-many" community, Sina Showcase.

Our communities offer diverse selection of user-generated content in the live social online video community industry. Through our "many-to-many" ecosystem where multiple users can simultaneously stream to other viewers in the same real-time video room, Tian Ge enables users to interact, socialize, share interest, send virtual items & gifts, and encourages our users to showcase their talents or knowledge for open and public exposure. Recently, we expanded our ecosystem to the online-to-offline (O2O) karaoke, live social games and emerging healthcare mobile applications.

For more information, please visit www.tiange.com  

To visit our communities:
9158: www.9158.com; Sina Show: http://show.sina.com.cn/; Sina Showcase: http://ok.sina.com.cn/

For media inquiries, please feel free to contact:

LBS Communications Consulting Limited

Joanne Chan (852-9616 2676), Janice Liu (852-9859 0513), Ian Fok (852-9348 4484)
Tel   : (852) 3679 3671 / (852) 3752 0428 / (852) 3752 0432
Fax : (852) 3753 2899
Email: jchan@lbs-comm.com / jliu@lbs-comm.com / ifok@lbs-comm.com

For investor inquiries, please contact:
Kenneth Ke
Tel: +86 (571) 88108686 Ext. 8103
Email: kenneth@9158.com

SOURCE Tian Ge Interactive Holdings Limited

Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, today announced several key changes to the Company's board of directors (the "Board") and management team.

Board of Directors
The Company announced today that both Mr. Ronald Schmeichel and Mr. John Huss would not be standing for re-election at the Company's annual general meeting of shareholders scheduled for June 25, 2015 (the "Meeting"). 

"I would like to thank Ron and John for the dedication and service they provided to Concordia during the past few years," stated Mark Thompson, Chief Executive Officer of Concordia. "In particular, I would like to thank Ron for his leadership in assisting with the establishment of Concordia. Ron was instrumental in Concordia's start-up financing and in taking the Company public. His guidance during that time was critical to Concordia's success."

Ron Schmeichel stated, "I am very proud to have served as the Chairman of Concordia while working alongside Mark Thompson to grow Concordia from a company with a market capitalization of approximately $30 million to almost $3 billion in two short years, and I look forward to focusing on building JJR Private Capital's other portfolio companies now that Concordia moves into a new phase of growth."

In their place, the Company is pleased to announce that Mr. Edward Borkowski and Ms. Rochelle Fuhrmann have been nominated for election as directors of the Company. Mr. Borkowski and Ms. Fuhrmann will join the Board effective June 25, 2015, subject to shareholder approval at the Meeting.

Mr. Borkowski has over 15 years of experience in executive financial positions in the pharmaceutical sector, and is currently the Chief Financial Officer of Amerigen Pharmaceuticals. Prior to joining Amerigen Pharmaceuticals, Mr. Borkowski held several executive level finance positions with various entities, notably as the Chief Financial Officer and Executive Vice President of Mylan N.V. Mr. Borkowski has an MBA in accounting from Rutgers University and a degree in Economics and Political Science from Allegheny College.

Ms. Fuhrmann has over 20 years of broad financial experience and was previously the Chief Financial Officer of Amneal Pharmaceuticals LLC. Prior to joining Amneal, Ms. Fuhrmann was Senior Vice President, Finance at Warner Chilcott plc, a specialty pharmaceuticals company, prior to its acquisition by Actavis, Inc. in 2013.  She spent the early part of her career in telecommunications and public accounting having held various positions at AT&T and Coopers and Lybrand LLC (now PricewaterhouseCoopers LLP).  Ms. Fuhrmann earned her certified public accountant designation (inactive) in 1996 and has a B.Sc. degree in accounting from the University of Rhode Island.

"On behalf of the nominating and corporate governance committee and the board of directors as a whole, I am very pleased to announce the nomination of Edward and Rochelle to the board of directors. This nomination is an important part of several recent and ongoing pharmaceutical industry leadership and corporate governance enhancement initiatives that have been undertaken by the Board," stated Mark Thompson.

Upon conclusion of the Meeting, it is planned that Mr. Thompson will replace Mr. Schmeichel as the Chairman of the Board and Jordan Kupinsky will become Lead Independent Director of the Board.

Management Team
The Company is also pleased to announce that Mr. Adrian de Saldanha has been appointed the Chief Financial Officer of the Company, which will take effect immediately. In his role as Chief Financial Officer, Mr. de Saldanha will succeed Mr. Leith Tessy.

Mr. de Saldanha is a Chartered Professional Accountant (CPA, CA) with extensive experience as a senior finance executive in roles covering a variety of industries. Most recently Mr. de Saldanha was Chief Financial Officer at Syncordia Technologies and Healthcare Solutions, Inc., previous to which he was a Managing Vice President at OMERS Strategic Investments where his responsibilities included management of investments in entities involved in aviation, engineering and industrial services. Mr. de Saldanha also spent over seven years at Biovail Corporation (now Valeant Pharmaceuticals) in a number of senior finance roles including Interim Chief Financial Officer, Vice President Finance & Treasurer, Vice President Manufacturing Finance as well as Vice President, Controller at Biovail Pharmaceuticals Canada.  Before joining Biovail, Mr. de Saldanha spent eight years at Molson Inc. in a number of progressively senior finance positions.

"I am very pleased to welcome Adrian to the Concordia team and look forward to working with him as we take the Company through the next phase of its development. Adrian's successful track record of overseeing company finances will provide valuable financial leadership and guidance to Concordia during its continued development," stated Mark Thompson.

Mr. Thompson added,"I would like to thank Leith for his hard work and dedication over the past two years and wish him the best in his future endeavours. Leith will remain available to the Company until September 1, 2015, to assist in the transition."

In addition, upon conclusion of the Meeting, it is planned that Mr. Thompson will relinquish his role as President of the Company and Mr. Wayne Kreppner will be promoted to the role of President, in addition to his role as Chief Operating Officer of the Company. 

"Wayne's dedication and efforts have been the underpinning of Concordia's operational success," stated Mr. Thompson. "In his new role he will be able to provide additional leadership to the team and further enhance operational success going forward."

Finally, the Company announced that Mr. Arikit Mookerjee has joined as Chief Financial Officer of Concordia Pharmaceuticals Inc. ("CPI"), the Company's Barbados subsidiary.  Prior to accepting this position with CPI, Mr. Mookerjee was a consultant for SMEC International Pty Limited, an Audit Director with PricewaterhouseCoopers LLP, and acted as the Group Financial Controller with Cordlife Limited a healthcare and stem-cell biotechnology firm.

"Mr. Mookerjee brings a strong financial background and will provide leadership to Concordia Pharmaceuticals Inc," stated Mr. Thompson.

Change of Auditor
The Company announced today that the auditors, Collins Barrow Toronto LLP, Chartered Accountants (the "Former Auditor") are not being proposed for re-appointment at the Meeting. At the Meeting, Concordia's shareholders will be asked to approve the appointment of PricewaterhouseCoopers LLP, as auditor of the Company. Subject to all applicable regulatory and shareholder approvals, effective upon conclusion of the Meeting, the Company's auditor will be PricewaterhouseCoopers LLP (the "Successor Auditor").

The Company advises that there were no reservations in the Auditor's Reports for either of the Company's two most recently completed fiscal years nor for any period subsequent thereto for which an audit report was issued and preceding the date hereof.

In the opinion of the Company's audit committee and the Board, there were no "reportable events" as defined in National Instrument 52-102 – Continuous Disclosure Obligations ("NI-51-102").

The Company's audit committee and the Board have approved the resignation of the Former Auditor. Pursuant to NI 51-102, the notice of change of auditor, together with the letter from the Former Auditor and the letter from the Successor Auditor have been reviewed by the Company's audit committee and Board and have been filed on SEDAR accordingly.

FTC Consent Decree
On February 9, 2015, Concordia and its subsidiary, CPI, received a civil investigative demand ("CID") from the United States Federal Trade Commission ("FTC") regarding its attention deficit hyperactivity disorder product Kapvay®.  The CID is a request for documents and information relating to CPI's agreements with Par Pharmaceutical, Inc. ("Par") with respect to Kapvay® (the "Par Agreements").  While Concordia maintains that the Par Agreements are lawful, it has negotiated the terms of a proposed settlement agreement with the FTC and expects to settle the FTC investigation.  The proposed agreement with the FTC does not constitute an admission by Concordia that it has violated the law.  Under the terms of the proposed settlement agreement, Concordia will be prohibited from enforcing the provision of the Par Agreements which entitle Concordia to a royalty payment corresponding to Par's sales of generic Kapvay® and from entering any future agreement with a generic company that would prevent the marketing of an authorized generic version of a branded drug after all patents have expired on the drug.  Concordia will also be subject to standard antitrust compliance and reporting requirements.  The proposed settlement agreement is subject to initial acceptance by the FTC, publication of the settlement's terms and a 30-day public comment period, and final acceptance by the FTC.

About Concordia
Concordia is a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs. Concordia's legacy pharmaceutical division, Concordia Pharmaceuticals Inc., consists of 23 high- margin products including Nilandron®, for the treatment of metastatic prostate cancer; Dibenzyline®, for the treatment of pheochromocytoma; Lanoxin®, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil®, for the treatment of lupus and rheumatoid arthritis, Donnatal® for the treatment of irritable bowel syndrome and Zonegran® (zonisamide) for treatment of partial seizures in adults with epilepsy. Concordia's orphan drugs division, Concordia Laboratories Inc., manufactures Photofrin®. Photofrin® is marketed by Pinnacle Biologics, Inc. in the United States.

Concordia operates out of facilities in Oakville, Ontario; Bridgetown, Barbados; Kansas City, Missouri; Chicago, Illinois and Charlottesville, Virginia.

Notice regarding forward-looking statements:
This news release includes forward-looking statements regarding Concordia and its business, which may include, but are not limited to, the composition of the Board, shareholder approval for Board nominees, and the benefits to be provided to the Company by new management appointees. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of Concordia's management, and are based on assumptions and subject to risks and uncertainties. Although Concordia's management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Concordia, including risks relating to the use of Concordia's products to treat certain diseases, the pharmaceutical industry, the failure to obtain regulatory or shareholder approvals, economic factors, market conditions, the equity markets generally, risks associated with growth and competition, general economic and stock market conditions and many other factors beyond the control of Concordia. Although Concordia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Concordia undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Concordia Healthcare Corp.

As part of efforts to increase awareness of thyroid health on today's 8th Annual World Thyroid Day, the Council for Responsible Nutrition (CRN) joins the American Thyroid Association (ATA) and its sister international thyroid societies in calling attention to the important functions regulated by a healthy thyroid. In particular, CRN is focusing on the role of iodine and its importance for thyroid and overall health, especially for women who are pregnant or lactating.

"Iodine is a nutrient that is critical for the production of thyroid hormones, and therefore, a deficiency in iodine can lead to thyroid hormone-related and other health problems," said Duffy MacKay, N.D., senior vice president, scientific and regulatory affairs, CRN. "Additionally, pregnant or nursing women who are getting insufficient amounts of iodine can put their children at risk for decreased cognitive function, which is why CRN, and medical organizations, including ATA, The American Academy of Pediatrics, and the Endocrine Society, recommend that women who are pregnant or lactating receive a daily multivitamin/mineral supplement that contains 150 mcg of iodine."

In addition to demonstrating iodine's essential role for the health of women of childbearing age, scientific evidence has shown that getting enough iodine can help in preventing thyroid gland dysfunction, such as goiter, and various abnormalities related to the nervous system, digestive system or skin.

According to Robert C. Smallridge, M.D., president, ATA, "Tens of millions of people worldwide are affected by diseases of the thyroid. With World Thyroid Day, we are emphasizing the need for greater education and ways to prevent thyroid-related health problems. We are glad to see CRN participating in this educational effort."

CRN's recommended guidelines, "Iodine Quantity in Multivitamin/Mineral Supplements for Pregnancy and Lactation," released this past January and applauded by the American Thyroid Association, can be found on CRN's website. For more information on World Thyroid Day, visit: www.thyroid.org.

Note to Editor: The Council for Responsible Nutrition (CRN), founded in 1973, is a Washington, D.C.-based trade association representing 150+ dietary supplement and functional food manufacturers, ingredient suppliers, and companies providing services to those manufacturers and suppliers. In addition to complying with a host of federal and state regulations governing dietary supplements and food in the areas of manufacturing, marketing, quality control and safety, our manufacturer and supplier members also agree to adhere to additional voluntary guidelines as well as to CRN's Code of Ethics. Visit www.crnusa.org. Follow us on Twitter @crn_supplements and @wannabewell and on Facebook.

SOURCE Council for Responsible Nutrition

Mylan N.V. (NASDAQ: MYL) today announced that it was asked by the Irish Takeover Panel to issue the following clarification and retraction in accordance with the Irish Takeover Rules (the "Rules"), relating to its firm intention to make an offer to acquire the issued and to be issued shares of Perrigo (NYSE: PRGO; TASE). The clarification and retraction relates to certain forward-looking statements made by Mylan specifically during The Pendency Of The Offer Period (the "offer period") concerning its long-stated target since 2012 of at least $6.00 in adjusted diluted earnings per share ("EPS") by 2018, including recently in Mylan's first quarter earnings press release of May 5, 2015.

Subsequent to the May 5 earnings release, Perrigo submitted a complaint to the Irish Takeover Panel alleging that the reference to Mylan's long-term target should be treated as a forward-looking profit forecast statement for purposes of the Rules, and therefore must comply with the terms of the Rules.

Although Mylan's longstanding adjusted diluted EPS goal has been a well stated long-term target, and not a forecast of Mylan, at least during the offer period as it pertains to the Perrigo transaction, Mylan will no longer refer to that 2018 target or any other forward looking statements beyond 2015 that could constitute profit forecasts under the Rules.

Mylan fully intends to continue to comply with all requirements of the Rules and asks that investors be mindful of these rules and therefore patient and respectful of these requirements during the pendency of the offer period.

ABOUT MYLAN
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. Our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.  

RESPONSIBILITY STATEMENT
The directors of Mylan N.V. ("Mylan") accept responsibility for the information contained in this communication. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case) the information contained in this communication is in accordance with the facts and does not omit anything likely to affect the import of such information.

DEALING DISCLOSURE REQUIREMENTS
Under the provisions of Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the "Irish Takeover Rules"), if any person is, or becomes, 'interested' (directly or indirectly) in, 1% or more of any class of 'relevant securities' of Perrigo or Mylan, all 'dealings' in any 'relevant securities' of Perrigo Company plc ("Perrigo") or Mylan (including by means of an option in respect of, or a derivative referenced to, any such 'relevant securities') must be publicly disclosed by not later than 3:30 pm (New York time) on the 'business' day following the date of the relevant transaction. This requirement will continue until the date on which the 'offer period' ends. If two or more persons co-operate on the basis of any agreement, either express or tacit, either oral or written, to acquire an 'interest' in 'relevant securities' of Perrigo or Mylan, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules.

Under the provisions of Rule 8.1 of the Irish Takeover Rules, all 'dealings' in 'relevant securities' of Perrigo by Mylan or 'relevant securities' of Mylan by Perrigo, or by any party acting in concert with either of them, must also be disclosed by no later than 12 noon (New York time) on the 'business' day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose 'relevant securities' 'dealings' should be disclosed, can be found on the Irish Takeover Panel's website at www.irishtakeoverpanel.ie.

Interests in securities arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an 'interest' by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the Irish Takeover Rules, which can also be found on the Irish Takeover Panel's website. If you are in any doubt as to whether or not you are required to disclose a dealing under Rule 8, please consult the Irish Takeover Panel's website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 1 678 9020 or fax number +353 1 678 9289.

Goldman Sachs, which is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting for Mylan and no one else in connection with the proposed acquisition of Perrigo by Mylan (the "Perrigo Proposal") and will not be responsible to anyone other than Mylan for providing the protections afforded to clients of Goldman Sachs, or for giving advice in connection with the Perrigo Proposal or any matter referred to herein.

Goldman Sachs does not accept any responsibility whatsoever for the contents of this communication or for any statement made or purported to be made by them or on their behalf in connection with the offer. Goldman Sachs accordingly disclaims all and any liability whether arising in tort, contract or otherwise which it might otherwise have in respect of this communication or any such statement.

ADDITIONAL INFORMATION
In connection with the Perrigo Proposal, Mylan has filed certain materials with the Securities and Exchange Commission (the "SEC"), including, among other materials, a Registration Statement on Form S-4 (that includes an offer to exchange/prospectus) on May 5, 2015 (which Registration Statement has not yet been declared effective) and a preliminary proxy statement on Schedule 14A on May 5, 2015. In connection with the Perrigo Proposal, Mylan intends to file with the SEC a Tender Offer Statement on Schedule TO and certain other materials. This communication is not intended to be, and is not, a substitute for such filings or for any other document that Mylan may file with the SEC in connection with the Perrigo Proposal. INVESTORS AND SECURITYHOLDERS OF MYLAN AND PERRIGO ARE URGED TO READ THE DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY (IF AND WHEN THEY BECOME AVAILABLE) BEFORE MAKING AN INVESTMENT DECISION BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MYLAN, PERRIGO AND THE PERRIGO PROPOSAL. Such documents will be available free of charge through the website maintained by the SEC at www.sec.gov or by directing a request to Mylan at 724-514-1813 or investor.relations@mylan.com. Any materials filed by Mylan with the SEC that are required to be mailed to shareholders of Perrigo and/or Mylan will also be mailed to such shareholders. This communication has been prepared in accordance with U.S. securities law, Irish law and the Irish Takeover Rules.

A copy of this communication will be available free of charge at the following website: perrigotransaction.mylan.com. Such website is neither endorsed, nor sponsored, nor affiliated with Perrigo or any of its affiliates. PERRIGO® is a registered trademark of L. Perrigo Company.

PARTICIPANTS IN SOLICITATION
This communication is not a solicitation of a proxy from any investor or shareholder. However, Mylan and certain of its directors, executive officers and other members of its management and employees may be deemed to be participants in the solicitation of proxies in connection with the Perrigo Proposal under the rules of the SEC. Information regarding Mylan's directors and executive officers may be found in the Mylan proxy statement/prospectus on Form S-4 filed with the SEC on December 23, 2014 and Mylan Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, which was filed with the SEC on March 2, 2015 and amended on April 30, 2015. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the interests of these participants, which may, in some cases, be different than those of Mylan's shareholders generally, will also be included in the materials that Mylan intends to file with the SEC when they become available.

NON-SOLICITATION
This communication is not intended to, and does not, constitute or form part of (1) any offer or invitation to purchase or otherwise acquire, subscribe for, tender, exchange, sell or otherwise dispose of any securities, (2) the solicitation of an offer or invitation to purchase or otherwise acquire, subscribe for, sell or otherwise dispose of any securities or (3) the solicitation of any vote or approval in any jurisdiction pursuant to this communication or otherwise, nor will there be any acquisition or disposition of the securities referred to in this communication in any jurisdiction in contravention of applicable law or regulation. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

FURTHER INFORMATION
The distribution of this communication in certain jurisdictions may be restricted or affected by the laws of such jurisdictions. Accordingly, copies of this communication are not being, and must not be, mailed or otherwise forwarded, distributed or sent in, into, or from any such jurisdiction. Therefore, persons who receive this communication (including, without limitation, nominees, trustees and custodians) and are subject to the laws of any such jurisdiction will need to inform themselves about, and observe, any applicable restrictions or requirements. Any failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, Mylan disclaims any responsibility or liability for the violations of any such restrictions by any person.

FORWARD-LOOKING STATEMENTS
This communication contains "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about the Perrigo Proposal, Mylan's acquisition (the "EPD Transaction") of Mylan Inc. and Abbott Laboratories' non-U.S. developed markets specialty and branded generics business (the "EPD Business"), the benefits and synergies of the Perrigo Proposal or EPD Transaction, future opportunities for Mylan, Perrigo, or the combined company and products, and any other statements regarding Mylan's, Perrigo's, or the combined company's future operations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations and targets for future periods. These may often be identified by the use of words such as "will," "may," "could," "should," "would," "project," "believe," "anticipate," "expect," "plan," "estimate," "forecast," "potential," "intend," "continue," "target" and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: uncertainties related to the Perrigo Proposal, including as to the timing of the offer and compulsory acquisition, whether Perrigo will cooperate with Mylan and whether Mylan will be able to consummate the offer and compulsory acquisition, whether Mylan shareholders will provide the requisite approvals for the Perrigo Proposal, the possibility that competing offers will be made, the possibility that the conditions to the consummation of the offer will not be satisfied, and the possibility that Mylan will be unable to obtain regulatory approvals for the offer and compulsory acquisition or be required, as a condition to obtaining regulatory approvals, to accept conditions that could reduce the anticipated benefits of the offer and compulsory acquisition; the ability to meet expectations regarding the accounting and tax treatments of a transaction relating to the Perrigo Proposal and the EPD Transaction; changes in relevant tax and other laws, including but not limited to changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; the integration of Perrigo and the EPD Business being more difficult, time-consuming, or costly than expected; operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients, or suppliers) being greater than expected following the Perrigo Proposal and the EPD Transaction; the retention of certain key employees of Perrigo and the EPD Business being difficult; the possibility that Mylan may be unable to achieve expected synergies and operating efficiencies in connection with the Perrigo Proposal and the EPD Transaction within the expected time-frames or at all and to successfully integrate Perrigo and the EPD Business; expected or targeted future financial and operating performance and results; challenges to our business and strategic plans posed by the recent unsolicited business proposal made by Teva Pharmaceutical Industries Ltd. to acquire all of our outstanding shares; the capacity to bring new products to market, including but not limited to where Mylan uses its business judgment and decides to manufacture, market, and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the courts (i.e., an "at-risk launch"); success of clinical trials and our ability to execute on new product opportunities; the scope, timing, and outcome of any ongoing legal proceedings and the impact of any such proceedings on financial condition, results of operations and/or cash flows; the ability to protect intellectual property and preserve intellectual property rights; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third- party relationships; the impact of competition; changes in the economic and financial conditions of the businesses of Mylan, Perrigo, or the combined company; the inherent challenges, risks, and costs in identifying, acquiring, and integrating complementary or strategic acquisitions of other companies, products or assets and in achieving anticipated synergies; uncertainties and matters beyond the control of management; and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with accounting principles generally accepted in the United States of America and related standards or on an adjusted basis. For more detailed information on the risks and uncertainties associated with Mylan's business activities, see the risks described in Mylan's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 and our other filings with the SEC. These risks, as well as other risks associated with Mylan, Perrigo, and the combined company are also more fully discussed in the Registration Statement on Form S-4 and the proxy statement that Mylan filed with the SEC on May 5, 2015 in connection with the Perrigo Proposal. You can access Mylan's filings with the SEC through the SEC website at www.sec.gov, and Mylan strongly encourages you to do so. Mylan undertakes no obligation to update any statements herein for revisions or changes after the date of this communication. Long-term targets, including, but not limited to, 2018 targets, do not represent Mylan guidance.

NO PROFIT FORECAST / ASSET VALUATIONS

No statement in this communication is intended to constitute a profit forecast for any period, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for Mylan or Perrigo as appropriate. No statement in this communication constitutes an asset valuation.

SOURCES AND BASES OF INFORMATION
The information set forth under "About Mylan" is extracted from Mylan Inc.'s Annual Report (Form 10-K) for the period ended December 31, 2014, filed with the SEC on March 2, 2015 and amended on April 30, 2015.

SOURCE Mylan N.V.

The leading companies in the cardiac defibrillator segment of the $13 billion global cardiac rhythm management device market dominate their competition, according to Kalorama Information.  Kalorama found that Medtronic, St. Jude Medical, Boston Scientific and Asahi Kasei (with ZOLL Medical) command 80% of this market segment. The healthcare market research publisher's report, Cardiac Rhythm Management Device Markets, uses 2015 as a base year, providing forecasts for each year through 2020.  The market is evaluated via a combination of disease prevalence trends, population trends, device innovations, federal and industry standards and regulations. 

Kalorama Information
Cardiac Rhythm Management Device Markets can be found at Kalorama Information: http://www.kaloramainformation.com/redirect.asp?progid=87484&productid=8911435.

"The cardiac defibrillator market is highly competitive and varies in participation by device segment," said Bruce Carlson, publisher of Kalorama. "The implantable segment, for instance, is dominated by a handful of companies and these providers maintain their hold on market penetration."

Cardiac defibrillators are electrical devices that deliver therapeutic levels of energy to the heart muscle for the treatment of ventricular defibrillation, cardiac dysrhythmias and pulseless ventricular tachycardia. Devices can be implanted in the body, external, or transvenous. The goal of the technology is to reestablish the normal rhythm of the heartbeat.

The implantable defibrillator device segment has gained wide acceptance over the past decade. Within this segment are advanced versions of the technology, including cardiac resynchronization therapy defibrillators (CRT-D). The external defibrillator device market consists of professional/manual defibrillators and automatic external defibrillators, commonly referred to as AEDs. The implantable transvenous cardioverter-defibrillator segment consists of devices implantable inside the body, able to perform both cardioversion, defibrillation and pacing of the heart.

In many markets, the top companies maintain their market edge through patented innovation. The cardiac defibrillator segment is no exception. Medtronic is listed in over 7,186 patents that describe medical devices, tissue-related systems, instrumentation, user interfaces, sensors, therapy systems, implantable devices, delivery devices, and monitoring technologies. There are 898 patents in the U.S. database under the St. Jude Medical name – for cardiovascular devices, implantables, sutures, fixation systems, ablation technology, an implantable system for measuring mechanical dyssynchronicity of the heart and catheters. Boston Scientific holds over 3,894 patents; recent technologies described in these patents include medical devices in neurostimulation, cardiology and other surgery. Asahi Kasei (with ZOLL Medical) has 105 patents in the U.S. patent database; recent patented technologies include systems for energy delivery, medical monitoring and a defibrillator with a light sensor. These market leaders use their patents to assert a level of control over their intellectual property and in so doing also help to maintain their market share.

Cardiac Rhythm Management Device Markets breaks down the cardiac rhythm device market into its segments, with market sizing and forecasts to 2020:
Sales of Cardiac Defibrillator by Type (External, Implantable)
Sales of External Defibrillators by Product Type, (AEDs, Professional/Manual Defibrillators)
Sales of Implantable Cardiac Defibrillators by Product Type, 2015 (Standard ICD, CRT-D)
Sales of Cardiac Pacemaker by External and Implantable Types
Sales of Implantable Cardiac Pacemakers by Product Type (Standard ICP, CRT-P)

As cardiovascular disease is an international problem and the focus of major world healthcare systems, the report also provides overall rhythm management device market size and forecasts (2010-2020) for each of the following countries: United States, Germany, UK, Italy, France, Spain, Brazil, China, Japan and Australia.

Primary sources for the report include telephone interviews and email correspondence with more than 100 key industry officials, consultants, health care providers, and government personnel on the topic of cardiac rhythm management.  These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. 

Cardiac Rhythm Management Device Markets can be found at Kalorama Information: http://www.kaloramainformation.com/redirect.asp?progid=87484&productid=8911435.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.  

Contact:
Bruce Carlson
(212) 807-2622
bcarlson@kaloramainformation.com
www.KaloramaInformation.com

Logo – http://photos.prnewswire.com/prnh/20140801/132634

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kalorama-top-companies-dominate-cardiac-defibrillator-market-300087910.html

SOURCE Kalorama Information